European Commission Approves Soliris® (eculizumab) for Treatment of Patients with Refractory gMG.
Read the press release for more information.

Seeing the Unseen for 25 Years

For 25 years, Alexion has seen opportunities where others have not. We have had the courage to explore what others believe is impossible. And we have forged a pathway from innovative science to breakthrough therapies for patients suffering from rare diseases that had previously been overlooked.

We see an opportunity to change lives.

We have the passion to engineer our own course because the scientific challenges we choose to tackle require it. We are driven by our mission to bring hope to patients and families affected by rare diseases by delivering innovative, life-changing therapies.

Latest News

view all news